The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Expansion Is Predicted For The G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Between 2026 And 2030?
The market for g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies has seen substantial growth in recent years. This market is projected to expand from $0.59 billion in 2025 to $0.78 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 32.7%. Historically, this growth has been driven by several factors, including advancements in targeted cancer therapy research, the increasing prevalence of multiple myeloma cases, the expansion of monoclonal antibody development programs, enhancements in clinical trial infrastructure, and rising investments in oncology drug discovery.
The g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market size is projected to experience significant expansion over the next few years. It is expected to grow to $2.42 billion in 2030 at a compound annual growth rate (CAGR) of 32.9%. This projected growth during the forecast period can be attributed to several factors, including increasing regulatory approvals for targeted biologics, a rising demand for personalized cancer treatments, the expansion of next-generation immunotherapy platforms, growing investments in precision medicine ecosystems, and the increasing adoption of biomarker-based therapy selection. Major trends foreseen in the forecast period include the increasing development of bispecific antibody therapies, a rising focus on gprc5d biomarker-driven patient selection, the growing adoption of CAR-T cell platforms, an expansion of precision oncology clinical pipelines, and enhanced integration of companion diagnostics.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=33116&type=smp
What Drivers Are Expected To Influence The G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market During The Forecast Period?
The increasing prevalence of myeloma is projected to drive the expansion of the GPRC5D-targeted therapies market in the future. Myeloma is characterized as a cancer affecting plasma cells within the bone marrow, leading to impaired normal blood cell formation and potentially resulting in bone damage, anemia, and kidney issues. The growing incidence of myeloma is partly attributable to an aging populace, given that the likelihood of developing plasma cell disorders increases with age as genetic mutations accumulate. These GPRC5D-targeted therapies aid in treating myeloma by attaching to the GPRC5D protein found on malignant plasma cells, thereby guiding the immune system, particularly T cells, to specifically eliminate these cancerous cells while largely preserving healthy ones. For example, the American Cancer Society, a US-based professional organization, stated in January 2026 that the United States is projected to register approximately 36,000 new cases of multiple myeloma in 2026, comprising 20,150 cases in men and 15,850 in women. Additionally, about 10,850 deaths are foreseen, with 5,780 among men and 5,070 among women. Consequently, the increasing prevalence of myeloma is a key factor propelling the expansion of the GPRC5D-targeted therapies market.
Which Market Segments Are Examined In The G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Study?
The g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market covered in this report is segmented –
1) By Therapy Type: Monoclonal Antibodies; Bispecific Antibodies; Chimeric Antigen Receptor (CAR-T) Cell Therapies; Other Therapy Types
2) By Indication: Multiple Myeloma; Solid Tumors; Other Indications
3) By Technology: Precision Medicine Approaches; Molecular Targeted Therapy; Cancer Immunotherapy Platforms; Biopharmaceutical Drug Delivery Systems
4) By Route Of Administration: Intravenous; Subcutaneous; Other Routes Of Administration
5) By End-User: Hospitals; Specialty Clinics; Research Institutes; Other End-Users
Subsegments:
1) By Monoclonal Antibodies: Fully Human Monoclonal Antibodies; Humanized Monoclonal Antibodies; Chimeric Monoclonal Antibodies; Murine Monoclonal Antibodies
2) By Bispecific Antibodies: Dual Targeting Bispecific Antibodies; Cross Linking Bispecific Antibodies; Immune Cell Engaging Bispecific Antibodies; Cytotoxic Bispecific Antibodies
3) By Chimeric Antigen Receptor (CAR-T) Cell Therapies: Autologous Car T Cell Therapies; Allogeneic Car T Cell Therapies; Next Generation Car T Cell Therapies; Gene Edited Car T Cell Therapies
4) By Other Therapy Types: Targeted Small Molecule Drugs; Receptor Specific Inhibitors; Injectable Biologics; Oral Targeted Therapeutics
Which Trends Are Influencing The G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market?
Leading companies within the GPRC5D targeted therapies market are dedicated to advancing innovative treatments, such as bispecific T cell engagers, to bolster immune-mediated targeting of cancer cells and enhance treatment effectiveness. A bispecific T-cell engager (BiTE) is an immunotherapy molecule engineered to forge a direct connection between T-cells and cancer cells by simultaneously binding to both, thereby activating T-cells to eradicate the targeted cancer cells. For example, in August 2023, Johnson & Johnson, a US-based healthcare firm, secured approval from the European Commission for TALVEY (talquetamab), a Janssen-developed bispecific antibody therapy specifically targeting GPRC5D. This approval is for patients with relapsed and refractory multiple myeloma (RRMM) who have undergone at least three prior therapies. This medication represents a first-in-class bispecific T-cell engager, designed to target GPRC5D on multiple myeloma cells and CD3 on T cells, offering a treatment option for relapsed/refractory multiple myeloma in heavily pretreated individuals. Its primary objective is to deliver sustained responses (demonstrating an ORR >70% in trials) even after at least four prior therapies, offering advantages such as convenient subcutaneous dosing, prolonged quality-of-life improvements, and proven efficacy even following previous bispecifics or CAR-T treatments, thereby addressing a critical unmet need in advanced-stage disease.
Which Companies Hold Significant Positions In The G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market?
Major companies operating in the g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market are Johnson And Johnson, F. Hoffmann-La Roche AG., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Bristol Myers Squibb Company, Genmab A/S, Genentech Inc., Simcere Zaiming Biotechnology Co. Ltd., Innovent Biologics Inc., Essen Biotech Co. Ltd., Nanjing IASO Biotechnology Co. Ltd., CARsgen Therapeutics Holdings Limited, Oricell Therapeutics Co. Ltd., Integral Molecular Inc., Overland Therapeutics Inc., Qilu Pharmaceutical Co. Ltd., Leads Biolabs Ltd., ShanghAI Yake Biotechnology Co. Ltd., Guangzhou Bio-gene Technology Co. Ltd.
Read the full g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market report here:
How Does The G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Perform Across Major Global Regions?
North America was the largest region in the GPRC5D targeted therapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=33116&type=smp
Browse Through More Reports Similar to the Global G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market 2026, By The Business Research Company
G Protein Coupled Receptors Market Report 2026
https://www.thebusinessresearchcompany.com/report/g-protein-coupled-receptors-global-market-report
Cc Chemokine Receptor Type 5 Market Report 2026
https://www.thebusinessresearchcompany.com/report/cc-chemokine-receptor-type-5-global-market-report
Gmp Cell Therapy Consumables Market Report 2026
https://www.thebusinessresearchcompany.com/report/gmp-cell-therapy-consumables-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model